Stockreport

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

2seventy bio, Inc.  (TSVT) 
PDF - Divestiture Supports Company Focus on Development and Commercialization of Abecma - CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced [Read more]